SCHEDULE: Dr. David Chang Updates Allogene Beneficial Ownership

Dr. David D. Chang and associated family trusts report a 4.9% beneficial ownership stake in Allogene Therapeutics, Inc.

Summary

• Dr. David D. Chang, M.D., Ph.D., filed an amendment to his Schedule 13G regarding his holdings in Allogene Therapeutics, Inc.
• The reporting group includes Dr. Chang, the Chang 2006 Family Trust, the JEC 2019 Trust, and the RTC 2019 Trust.
• The aggregate beneficial ownership reported is 12,297,354 shares of common stock.
• This total includes 6,345,007 shares issuable upon the exercise of stock options exercisable within 60 days of March 31, 2026.
• The reported ownership represents 4.9% of the company's outstanding common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting a change in ownership status rather than a fundamental shift in company strategy or performance.

Positives

• The filing confirms significant alignment of interest between the company's leadership and shareholders through substantial equity and option holdings.

Negatives

• The reporting person's total beneficial ownership has fallen below the 5% threshold, which may indicate minor divestment or dilution relative to the total outstanding shares.

Risks

• Concentration of voting power in the hands of a single individual and associated trusts.
• Reliance on stock option exercises for a significant portion of the reported beneficial ownership.

Future Outlook

No specific forward-looking guidance regarding company operations or future trading activity was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by company insiders are standard regulatory requirements to ensure transparency regarding significant equity positions, particularly in the volatile biotechnology sector where insider confidence is closely monitored by institutional investors.

Comparison to Industry Standards

• The filing adheres to standard SEC disclosure requirements for beneficial ownership reporting under the Securities Exchange Act of 1934.

Related Party Transactions

• The filing discloses holdings by the Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, for which Dr. Chang serves as co-trustee.

Stakeholder Impact

• Provides transparency to shareholders regarding the equity position of a key insider.

Next Steps

• Continued monitoring of future Form 4 filings for any subsequent changes in Dr. Chang's equity position.

Key Dates

Keywords

Allogene Therapeutics, David D. Chang, Schedule 13G, Beneficial Ownership, Biotech, Insider Holdings